Anika Therapeutics, Inc. (ANIK) Reports Q3 EPS of 22c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.50 --0%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
VISL, GNLN, USDP, More
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
VISL, GNLN, USDP, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.22, vs. the analyst estimate of $0.11. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
- Investcorp Credit Management BDC, Inc. (ICMB) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
